Avinger Inc (AVGR)

Avinger, Inc. (AVGR) is a commercial stage medical device company that designs and develops the first ever image guided,catheterbased  system  for  the  diagnosis  and  treatment  of  patients  with  peripheral  artery  disease  (PAD).  The  Sage  Group projected that over 21 million people in the U.S. alone will suffer from PAD by 2020. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusio (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger also markets the Wildcat and Kittycat2 endovascular catheters for CTO crossing. Avinge's Lumivascular and

endovascular treatment are FDA cleared, CE Marked, and commercially available in the U.S. and select international markets. The Company has five new products in the pipeline for future revenue opportunities, each representing ~$100 to ~$300 million market opportunities. Avinger's Lumivascular platform is the only technology that offers real time visualization of the inside of the artery during PAD treatment via optical coherence tomography (OCT), a high resolution, light based, radiation free imaging technology. The Lumivascular platform provides physicians a clear picture inside the artery during treatment, enabling them to better differentiate between plaque and healthy arterial structures while avoiding damage to healthy portions of an artery. It significantly improves procedural safety. According to MarketsandMarkets, the peripheral vascular device global market will reach$12.6 billion by 2022. Global Market Estimates projects that the worldwide CTO devices market will reach $1.8 billion by 2025.

Avinger's Management is committed to lowering costs, revamping products, and increasing revenue across the board. Avingerhas 120 patents and pending applications.  Avinger is based in Redwood City, California